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HLA preferences for conserved
epitopes: a potential mechanism
for hepatitis C clearance
Xiangyu Rao1†, Ilka Hoof 1†, Debbie van Baarle2‡, Can Kes¸mir 1 and Johannes Textor 1*
1 Theoretical Biology and Bioinformatics, Utrecht University, Utrecht, Netherlands, 2 Laboratory of Translational Immunology,
Department of Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Hepatitis C virus (HCV) infections affect more than 170million people worldwide. Most of
these individuals are chronically infected, but some clear the infection rapidly. Host factors
seem to play a key role in HCV clearance, among them are the human leukocyte antigen
(HLA) class I molecules. Certain HLA molecules, e.g., B*27 and B*57, are associated
with viral clearance. To identify potential mechanisms for these associations, we assess
epitope distribution differences between HLA molecules using experimentally verified and
in silico predicted HCV epitopes. Specifically, we show that the NS5B protein harbors the
largest fraction of conserved regions among all HCV proteins. Such conserved regions
could be good targets for cytotoxic T-cell (CTL) responses. We find that the protective
HLA-B*27molecule preferentially presents cytotoxic T-cell (CTL) epitopes fromNS5B and,
in general, presents the most strongly conserved epitopes among the 23 HLA molecules
analyzed. In contrast, HLA molecules known to be associated with HCV persistence do
not have similar preferences and appear to target the variable P7 protein. Overall, our
analysis suggests that by targeting highly constrained – and thereby conserved – regions
of HCV, the protective HLA molecule HLA-B*27 reduces the ability of HCV to escape the
cytotoxic T-cell response of the host. For visualizing the distribution of both experimentally
verified and predicted epitopes across the HCV genome, we created the HCV epitope
browser, which is available at theory.bio.uu.nl/ucqi/hcv.
Keywords: hepatitis C virus, sequence conservation, HLA disease association, peptide-MHC binding predictions,
CTL responses
1. INTRODUCTION
Hepatitis C virus (HCV) is a severe infectious agent and affects millions of people per year (1).
Approximately 25% of the infected individuals spontaneously resolve the infection, whereas most
develop a persistent viral infection, which may lead to liver cirrhosis, liver failure, or hepatocellular
carcinoma (2). Although the determinants of HCV clearance, persistence, and disease outcome
are not well known, it has been shown in numerous studies that the magnitude, diversity, and
quality of T-cell responses play an essential role in controlling the infection and determining
the outcome of HCV infection (3–6). Especially, efficient (CD4+) T-cell responses against non-
structural proteins might be important for viral control (7, 8). The importance of T-cell responses is
also supported by the finding that certain human leukocyte antigen (HLA) molecules are associated
with differential HCV infection outcome. Numerous HCV-HLA association studies have been
performed covering different ethnic groups and different HCV genotypes [reviewed in Ref. (9, 10)].
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Interestingly, two allele groups, B*27 and B*57, which have pre-
viously been associated with slow disease progression in HIV-
1-positive individuals [reviewed by Bashirova et al. (11)], are
also associated with viral clearance in HCV infection. For HLA
molecules in these groups, which we will call protective alleles,
several dominantly targeted CTL epitopes have been identified.
These epitopes were shown to contain mutations in individuals
unable to clear the HCV infection (12, 13) and lead to fitness loss
(14, 15) unless restored by compensatory mutations.
The HCV genome encodes a polyprotein precursor of about
3000 amino acid residues, which is processed into several mature
structural proteins (Core, E1, E2) and non-structural proteins
(NS2, NS3, NS4A, NS4B, NS5A, NS5B, P7) (16). A possible
mechanism behind the observed associations between certain
HLA class I molecules and HCV infection outcome could be
the differential presentation of HCV proteins by certain HLA
molecules, as was shown to be the case for HLA associations with
HIV-1 (17) and HTLV-1 (18). Such protein targeting could be
beneficial for various reasons. For instance, the targeted proteins
could be highly expressed, or the timing of their expression could
exhibit a critical period which is essential for viral replication.
Alternatively, a targeted protein could harbor many conserved
epitopes in which mutations would come at a high fitness cost,
making it more difficult to escape from the CTL response. Here,
we therefore address two related questions: (1) Is there evidence
for differential presentation of HCV proteins by protective alleles?
and (2) Do protective alleles target conserved regions of the HCV
genome?
To address these questions, we analyzed the HCV epitope
repertoires of several HLA molecules that have been associ-
ated with viral clearance or persistence, employing experimental
data from public databases and in silico predictions of HLA-
peptide binding to define these HLA epitope repertoires. We
found that the protective HLA molecule B*27 shows a preference
to present epitopes from the HCV protein NS5B, whereas other
HLA molecules show no preferential targeting or target other
HCV proteins such as P7. Analyzing the sequence variability
of HCV proteins, we found that NS5B harbors the largest frac-
tion of strongly conserved regions among all HCV proteins and
that the predicted B*27 epitope repertoire contains the largest
amount of strongly conserved epitopes of all alleles that were ana-
lyzed. Taken together, our analysis suggests a relationship between
the protective potential of an HLA molecule and the degree of
sequence conservation of the HCV epitopes targeted by that HLA
molecule.
2. MATERIALS AND METHODS
2.1. Experimentally Verified HCV
T-Cell Epitopes
All experimentally verified HCV CD8+ T-cell epitopes restricted
by HLA class I molecules were downloaded (October 2014)
from two public databases: (1) the Los Alamos HCV immunol-
ogy database1 [Ref. (19); note that maintenance of this database
1http://hcv.lanl.gov/content/immuno/immuno-main.html
stopped in 2007] and (2) the Immune Epitope Database and
Analysis Resource2 (IEDB (20)). HCV is classified into 7
phylogenetically distinct genotypes (21). As HCV genotype 1 is
the most dominant strain worldwide and is well studied (22), we
aligned each known epitope to the HCV reference strain H77
(accession number AF009606) using the blastp program (23).
Only those epitopes forwhich an alignmentwith 100% source cov-
erage could be found were included in the analysis. To make sure
that all epitopes we considered are from the HCV strains infecting
humans, epitopes identified using HLA transgenic mammalian
cells were excluded. This procedure resulted in 398 experimentally
verified combinations of an HCV genotype 1 CTL epitope and
its known HLA restriction (26 peptides appear in more than
one combination). Only 7 epitopes were restricted by HLA-C
molecules. To calculate the distribution of CTL epitopes over the
HCV proteins for each HLA allele, we limited our analysis to 263
non-redundant experimental epitopes: whenever multiple epi-
topes aligned to the same positions in the H77 reference strain, we
only included the epitope with the highest alignment score. The
final set of curated epitopes, which forms the basis for Figure 1, is
provided as supplementary data (Data Sheet S1 in Supplementary
Material).
2.2. HLA-Peptide-Binding Predictions
We used the artificial neural network-based MHC binding pre-
dictor NetMHCpan 2.8 (24) to predict MHC binding affinities
for 9-mer peptides from the HCV reference strain H77 (acces-
sion number AF009606). For every allele group, 2-digit reso-
lution, we have performed the predictions for the most domi-
nant allele, 4-digit resolution. Alternatively, we predicted MHC
binding for common HLA-A and HLA-B alleles by using the
Stabilized Matrix Method (25), but we found that this did not
affect the conclusions drawn from our analysis so we omit
these data from the present article for the sake of simplic-
ity. We also performed a version of our analysis in which
we additionally used the algorithm NetChop (26) to predict
proteasomal cleavage and transportation by TAP, which are
important selection steps during peptide generation for anti-
gen presentation. Also this analysis gave results similar to those
reported here.
2.3. Sequence Conservation
Prealigned HCV protein sequences (Core, E1, E2, NS2, NS3,
NS4A, NS4B, NS5A, NS5B, and P7 sequences) dated 2008 or
older were downloaded (October 2014) from the Los Alamos
HCV sequence database. The alignments contain only the “oldest”
sequence per patient based on their GenBank submission date and
cover sequences from all HCV genotypes. To estimate sequence
conservation, the Shannon entropy
E(i) =  
X
L
pL log2(pL)
was calculated for each position i of each protein, where pL is
the observed frequency of a certain amino acid L at position i
2http://www.immuneepitope.org/
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A B C
FIGURE 1 | NS5B is enriched in experimentally verified epitopes restricted by protective HLA allele groups (HLA-B*27, HLA-B*57). (A) The distribution of
(non-redundant) experimentally verified epitopes restricted by the protective alleles. (B) The distribution of all non-redundant HCV epitopes reported in the IEDB and
LANL databases. (C) The normalized length of each protein in the complete HCV proteome. The abundance of NS5B in (A) significantly differs from what would be
expected based on the distributions in (B) (p=0.0006) and (C) (p= 0.006; Fisher’s exact test).
in the alignment. The Shannon entropy for position i reaches its
maximum value of log2(20) (4.3) if all amino acids are equally
frequent at that position and is 0 if the position is fully conserved.
Different numbers of sequences were available for different HCV
proteins, ranging from 466 sequences for NS5B to 918 sequences
for NS3. To prevent a bias due to different numbers of sequences
in the alignments, we used the Miller-Madow entropy estima-
tor which corrects for such bias (27). We repeated this analysis
separately for sequences of HCV genotype 1.
To map sequence conservation of the HCV genome at the
spatial resolution that is most relevant for epitope presenta-
tion, we applied a running median filter with window size nine
to obtain an estimate of the overall conservation of a nine-
mer centered at the respective position. The window size nine
was chosen because it matches the typical length of peptides
presented by HLA class I molecules. The first and last four
positions of each protein were not assigned a median entropy,
as no nine-mer is centered at these positions. We chose the
median filter instead of other alternatives such as a running
average because the distribution of entropies is strongly skewed.
In order to separate strongly conserved regions from more vari-
able regions, we applied a threshold of 0.037 bits – the lower
quartile of the overall entropy distribution in the HCV pro-
teome. Changing this threshold did not affect the qualitative
results.
2.4. Statistical Analysis
All statistical analysis was performed using the R environment
(28). To analyze the targeting of proteins by HLA alleles, we
ranked the 9-mer peptides from each protein by their predicted
binding affinities and considered the n best-ranking peptides
as epitopes, where n was varied as described in the results.
We then compared the resulting distribution of epitopes across
proteins to the distribution expected from a random order-
ing of the peptides. We used a chi-square test to investigate
the significance of the difference between the expected and
observed distributions and computed standardized residuals for
each HLA-protein combination to assess the sources of those
differences.
TABLE 1 | HLA class I allele groups with significant associations with HCV
viremia as reported by Kuniholm et al. (9).
Allele
groupa
HCV RNA
status
Reference Population Nepb
B*18 Persistence (29) Irish 1
B*27 Clearance (29) Irish 6
B*57 Clearance (9, 12, 30, 31) Mixed 4
Cw*01 Clearance (9, 29, 30) Caucasian 0
Cw*04 Persistence (30, 32) Caucasian, Irish 0
aTwo-digit resolution.
bNumber of genotype 1 CTL epitopes identified so far (counting only non-redundant
epitopes; see Materials and Methods).
3. RESULTS
3.1. HCV-HLA Associations and
Analysis of Known HCV Epitopes
We studied the HLA restriction of all known CTL epitopes from
the HCV LANL and IEDB databases (see Methods). Kuniholm
et al. (9) conducted a literature review of HCV-HLA associa-
tions. Using stringent selection criteria, the authors identified
five HLA class I allele groups (B*18, B*27, B*57, Cw*01, and
Cw*04) that are strongly associated with either HCV clearance
or persistence (Table 1). Interestingly, the two allele groups B*27
and B*57, which are strongly associated with slow disease pro-
gression in HIV-1-positive individuals, are also associated with
a favorable infection outcome in HCV-infected patient cohorts.
Next, Kuniholm et al. (9) tested the association of HLA alleles
with HCV viremia in a large cohort of HCV-seropositive women
and confirmed all the associations, except for B*18, though the
effects were not always significant. Of the list of protective HLA
allele groups, multiple CTL epitopes have only been reported
for B*27 and B*57 (Table 2). We observed that 6 out of the 10
experimentally verified HCV CD8+ T-cell epitopes restricted by
the protective HLA allele groups are located in the HCV protein
NS5B, whereas the remaining 4 epitopes are distributed over 4
otherHCVproteins (Figure 1A). The share ofNS5B epitopes from
B*57 and B*27 is larger than would be expected from the distribu-
tion of all known epitopes across HCV proteins (Figure 1B) or the
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TABLE 2 | Experimentally verified CTL epitopes restricted by protective HLA
alleles (used in Figure 1A).
Epitope Protein Positiona HLA Predicted
IC50 (nM)b
GRGKPGIYRF NS3 466–475 HLA-B*27 1195
KGGRKPARLIVFPDL NS5B 151–165 HLA-B*27 484
ARHTPVNSW NS5B 400–408 HLA-B*27 1447
ARMILMTHF NS5B 421–429 HLA-B*27 129
GRAAICGKY NS5B 516–524 HLA-B*27 122
GRWVPGAAY P7 34–42 HLA-B*27 100
NTRPPLGNWF E2 158–167 HLA-B*57 241
LTTSQTLLF NS4B 90–98 HLA-B*57 306
KSKKTPMGF NS5B 209–217 HLA-B*57 121
LGVPPLRAWR NS5B 492–501 HLA-B*57 157
aPosition with respect to the HCV reference strain H77.
bFor peptides longer than 9 amino acids, the nine-mer with the best binding affinity is
shown in bold italics, and this is the binding affinity reported in the last column.
protein length (Figure 1C). Thus, this small set of experimentally
verified epitopes suggests that the epitopes of protective alleles are
concentrated in the NS5B protein.
3.2. Preferential Targeting Patterns of HCV
Proteins by Class I HLA Molecules
The power of our analysis of experimental epitopes is limited
because for many alleles, no CTL epitopes have been reported
yet. We therefore used in silico binding prediction as an alter-
native approach to define HLA epitope repertoires (see Mate-
rials and Methods for details). The cohort used by Kuniholm
et al. (9) to define protective allele groups (Table 1) was largely
infected with HCV genotype 1 (55% with genotype 1a, 29%
with genotype 1b, and 4% with genotype 1 of undetermined
subtype). Therefore, we assumed that the associations identified
by Kuniholm et al. (9) should be valid in the context of HCV
genotype 1 infection and used the genotype 1 reference strain
H77 from the LANL HCV database (19) for our predictions.
The HLA-binding affinities of all HCV peptides of length nine
were estimated for several HLA alleles using the prediction tool
NetMHCpan (see Materials and Methods). This method predicts
an IC50 value of <500 nM for 8 out of the 10 known HLA-B*27
and HLA-B*57 epitopes that are part of Figure 1A (Table 2).
Therefore, the in silico predictions should be a valid approach
to overcome the limited number of experimentally identified
epitopes.
In a first attempt to study preferential targeting of HCV pro-
teins by protective and susceptible HLA alleles, we followed the
strategy taken in previous studies on HIV-1 (17) and HTLV-
1 infection (18). We ranked the predicted HCV epitopes by
their predicted HLA-binding affinity within all HCV proteins
and then determined the ranks of the two best-binding peptides
derived from each HCV protein among all other HCV epitopes
(Figure 2). These ranks are expected to depend on the protein
length (Figure 1C): shorter proteins are less likely to contain
many top-ranking peptides than long proteins. This intuition was
confirmed for the NS4A protein, which is the shortest of the
HCV proteins (56 amino acids). Interestingly, the ranks for the
second shortest protein P7 (64 amino acids) were much higher
and comparable to the other proteins. However, this analysis
did not show any convincing differences between protective and
susceptible alleles (Figure 2).
We reasoned that focusing only on the top two binders might
not be an optimal approach because of the low number of peptides
involved, which is expected to produce significant uncertainty
with respect to the ranking. Thus, we decided to alternatively
look at the whole set of peptides that are predicted to bind each
HLA class I molecule. The fraction of peptides bound by each
HLA is normally considered to be around 2%. We therefore
looked at the top 30–120 binders (corresponding to 1–4% of
the HCV proteome, respectively) and compared the observed
distribution of proteins among those binders to the expected
distribution based on the protein length. Overall, HLAs seem to
deviate significantly from uniform protein targeting (p= 0.007,
chi-square test, for the 120 binders cutoff). To investigate which
HLA-protein combinations gave rise to the difference between the
observed protein targeting and a uniform targeting based only
on protein length, we investigated the standardized residuals of
the chi-square test. Standardized residuals measure the difference
between an observed frequency and the expected frequency; a
positive residual means that a combination occurs more often
than expected, whereas a negative residual means that it occurs
less often than expected. The magnitude of the residual gives an
indication of statistical significance. For instance, a standardized
residual of 2 or 2means that the difference is twice as large as the
standard error in measuring the expected frequency and roughly
corresponds to a significance level of = 0.05. In the following,
we will call the residuals enrichment scores.
In contrast to the previous analysis (Figure 2), the enrichment
scores revealed differential targeting for many HLA molecules.
Specifically, plotting the scores as a function of the cutoff shows
that HLA-B*2705, but none of the other protective or susceptible
HLA alleles, targets NS5B (Figure 3A). We also performed a two-
dimensional analysis of the targeting patterns of all HLA-protein
combinations by averaging the standardized residuals across the
cutoffs from 60 to 120 (Figure 3B), which showed a rich pattern
of protein targeting by many HLA alleles. Including a filter of the
predicted HLA ligands for their probability to be generated by the
proteasome (26) does not appreciably change these results (data
not shown).
Taken together, both the experimentally determined and the
predicted epitope repertoires indicate that the protective HLA-
B*27:05 allele targets the NS5B protein of HCV.
3.3. Identifying Strongly Conserved
Regions of the HCV Genome
Targeting NS5B could be important for several reasons. For exam-
ple, NS5B could be expressed in infected cells in large amounts or
early during the infection, resulting in both cases in an efficient
antigen presentation and a good CTL response. Unfortunately,
little is known about the expression of HCV proteins in infected
cells. Alternatively, since HCV is known to escape CTL pressure
by continuous evolution (33), CTL responses to structurally and
functionally constrained parts of the HCV genome are likely to
be most beneficial. Thus, a possible mechanism how targeting of
NS5B by HLA-B*27 would increase the odds of viral clearance
could be thatNS5Bharborsmany constrained epitopes. Therefore,
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FIGURE 2 | Binding affinity rankings of the best epitopes do not differ between susceptible and protective alleles. The relative ranks of epitopes from
each HCV protein are plotted for the protective (B*5701, B*2705, and Cw*0101; filled circles) and susceptible (B*1801, Cw*0401; open circles) HLA alleles (see
Table 1). The median of each group is indicated by a horizontal line. The relative rank is calculated with respect to the binding scores of all peptides from the HCV
proteome and separately for each HLA allele. None of the differences between susceptible and protective alleles are significant at = 0.05.
A
B
FIGURE 3 | HLA-B*27 targets the NS5B protein. (A) Enrichment score (standardized residual; explained in main text and Materials and Methods) as a function of
the rank cutoff between epitopes and non-epitopes. For example, at a cutoff of 60, the epitope repertoire consists of the 60 best binders and the proportion of
predicted epitopes from a given protein is compared with the proportion that would be expected based on the protein length. An enrichment score of 2 roughly
corresponds to significance at = 0.05 and a score of 2.58 corresponds to = 0.01 (gray horizontal line). The top 60 binders correspond to the top 2% binders in
HCV. (B) Matrix plot of enrichment scores per protein-HLA combination. Enrichment scores in each cell are averaged over cutoffs between 60 and 120 (or the top
2–4%). For clarity, all cells that would not be individually significant at the = 0.05 are muted (white cells). *These proteins are shorter than 100 amino acids (aa).
Therefore, the enrichment scores are based on only a few peptides. The protein lengths are CORE 191aa; E1 192aa; E2 363aa; P7 63aa; NS2 217aa; NS3 631aa;
NS4A 54aa; NS4B 261aa; NS5A 448aa; and NS5B 591aa.
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FIGURE 4 | NS5B is the most conserved HCV protein. Protein variability was estimated using bias-corrected Shannon entropy scores calculated for each
position in HCV protein alignments (see Materials and Methods). For each protein, the plot shows raw entropies (gray bars) and median entropies in nine-mers (black
lines) estimated from all sequences (plotted upward) or genotype 1 sequences only (plotted downward; see inset for the scale). Blue arrows point to the centers of
experimentally verified HLA-B*27 epitopes (see Figure 1). Strongly conserved nine-mers with low median entropy (see Materials and Methods and main text for
details) are highlighted in red. According to the coverage by strongly conserved nine-mers (shown to the right of each plot), NS5B is the most conserved HCV protein
(49%). The number of sequences per protein varies between 466 (NS5B) and 918 (NS3).
we sought to identify conserved regions in the HCV genome and
to compare their locations with those of HLA-B*27 epitopes.
The relative variability of HCV proteins was assessed by esti-
mating the average Shannon entropy of all positions for each
protein using prealigned amino acid sequences from all genotypes
available from the Los Alamos HCV database. Each of these
alignments includes only one sequence per patient. In order to
allow for direct comparison between the proteins, we corrected
for the number of sequences per protein alignment (see Materials
and Methods). We then identified strongly conserved regions in
the HCV genome as nine-mers in which the median entropy was
lower than the lower quartile of the overall entropy distribution;
this was the case for about 10% of all nine-mers in the genome.
Not surprisingly, strongly conserved regions are not uniformly
distributed across HCV proteins (Figure 4). Almost half of the
sequence of NS5B and Core are covered by strongly conserved
regions, whereas such regions are not found at all in the NS2,
NS4A, and P7 proteins. The degree of conservation probably
reflects the structural flexibility of these proteins: the structural
protein Core, for example, constitutes the capsid of the virus
particle and affects several cellular processes (34). For most of the
HCV proteins, however, the functional and structural constraints
are not yet known. The number of sequences available is not
evenly distributed over the different HCV genotypes. Therefore,
we could only repeat the conservation analysis on a genotype basis
for genotype 1, as the number of available sequences per protein
is less than 50 for the other genotypes. The sequence conservation
within genotype 1 (plotted downward in Figure 4) largely mirrors
the conservation across all genotypes (plotted upward), a notable
exception being theNS4A protein which is quite conservedwithin
genotype 1 but highly variable across all genotypes.
3.4. Presentation of Strongly Conserved
Epitopes by HLA-B*27
We mapped the six experimentally identified HLA-B*27 epitopes
to themultiple sequence alignment used for assessing variability of
theHCVgenome (blue arrows inFigure 4). Four of the epitopes lie
within or border of strongly conserved regions of NS5B and NS3,
one lieswithin a less conserved region ofNS5B, and one is found in
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the short highly variable P7 protein.While these sequence conser-
vation of these epitopes thus largely reflects the average sequence
conservation of the proteins themselves, the small number of
known HLA-B*27 epitopes does not allow meaningful statistical
assessment.
Therefore, we also analyzed the localization of in silico pre-
dicted epitopes for all HLA alleles used in Figure 3 using the
top 30, 60, and 120 binders, which correspond to the top 1%,
2%, and 4%, as explained above. For all three cutoffs, HLA-B*27
is predicted to present the largest number of strongly conserved
epitopes of all the HLA alleles that were analyzed (Figure 5),
whereas such a preference was not found for HLA-B*57. As
was the case for the few experimentally verified epitopes, the
epitope conservation level of the predicted epitopes mirrors the
protein targeting pattern (Figure 3): indeed, 11 of the 16 strongly
conserved predicted epitopes for HLA-B27 lie within NS5B (60-
binders cutoff; Table 3).
Taken together, the in silico analysis as well as our analysis based
on a limited number of known HCV CD8+ T-cell epitopes both
suggest that the protective HLA allele HLA-B*2705 associated
with clearance of HCV viremia tends to target conserved regions
within the NS5B protein, whereas many other HLA molecules
target different (and less conserved) regions of the HCV genome.
However, the in silico analysis did not confirm such an effect for
the other protective HLA alleles.
4. DISCUSSION
Several studies have shown that both CD4+ and CD8+ T-
cell responses play important roles in controlling HCV replica-
tion during infection (3–6), and certain HLA alleles have been
significantly associated with differential infection outcome (9).
The underlying mechanism behind these associations remains
unclear. In case of HIV-1 and HTLV-1, it was shown that the
immune system can effectively control infectious diseases by tar-
geting certain pathogen-derived proteins (17, 18). Similarly, other
studies found that T-cell epitopes are not equally distributed over
the genome of HIV-1 and M. tuberculosis but that they cluster
together in conserved regions (35–37). We hypothesized that tar-
geting of conserved regions within the HCV proteome by HLA
alleles could be a potential mechanism to control viral replication
during the acute phase ofHCV infection,which could then further
determine disease outcome.
To test this hypothesis, we performed a literature study to
compile a list of protective and susceptible HLA alleles. This
turned out to be rather difficult due to limited data and differences
between ethnic groups. Using the five strong HLA class I/HCV
associations defined by Kuniholm et al. (9) as a basis for our anal-
ysis, we found that experimentally verified CD8+ T-cell epitopes
restricted by the protective HLA molecules HLA-B*27 and HLA-
B*57 are enriched within the NS5B protein. When carrying out a
similar analysis using in silico predicted epitopes, we could only
see a preference for presentation of NS5B by HLA-B*2705, but
not for HLA-B*57:01. Interestingly, however, for precisely this
HLA-protein combination, several epitopes have been identified
for which mutations appear to have a high fitness cost (15, 38).
In line with previous studies (39), we found that NS5B is the
FIGURE 5 | HLA-B*27 presents the most conserved HCV epitopes. For
each HLA supertype, the number of strongly conserved epitopes among the
top 30 (black), top 60 (gray), and top 120 (white) predicted binders is shown.
HLA-B*27 shows the largest fraction of highly conserved epitopes for all three
thresholds.
TABLE 3 |Predicted HLA-B*27 epitopes that have both low entropy and high
binding affinity.
Epitope Protein Positiona Entropy (bits)b Predicted
IC50 (nM)
RRGPRLGVR CORE 39–47 0.03 132
SRCGSGPWI E2 212–220 0.037 1003
YRLWHYPCT E2 230–238 0.037 586
RRGRTGRGK NS3 461–469 0.036 234
NRLIAFASR NS4B 206–214 0.018 865
ERLYVGGPL NS5B 258–266 0 786
YRRCRASGV NS5B 276–284 0.024 491
RRCRASGVL NS5B 277–285 0.024 115
ARAAWETAR NS5B 393–401 0.024 156
QRLHGLSAF NS5B 464–472 0.024 496
LRKLGVPPL NS5B 489–497 0 438
RKLGVPPLR NS5B 490–498 0 824
LRAWRHRAR NS5B 497–505 0.024 251
WRHRARSVR NS5B 500–508 0.024 238
HRARSVRAR NS5B 502–510 0.024 264
ARSVRARLL NS5B 504–512 0.024 170
aPosition with respect to the HCV reference strain H77.
bThe median entropy in the nine-mer.
most conserved protein, followed by Core and NS3, while the
other proteins harbor more highly variable regions. Combined
with these results, our study thus suggests that the protective effect
of HLA-B*2705 might be mediated by preferential targeting of
conserved epitopes.
Unexpectedly, we found that quite many HLA class I alle-
les seem to preferentially present epitopes from the P7 protein
(Figure 3B), which according to our analysis does not harbor
any conserved regions. It is interesting to observe that the HLAs
targeting P7 include the two detrimental alleles B*18 and Cw*04.
Given that P7 is also the protein whose functional role for HCV
infection is most unclear (40), it is tempting to speculate that the
P7 targeting prevents those HLAs from inducing more protective
responses to other proteins. However, two caveats are that (1) the
protective allele Cw*01 also targets P7 and (2) P7 is the second
shortest HCV protein, hence the uncertainty involved in ranking
its best epitopes is high compared to longer proteins like NS5B.
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HCV genotype differences also play a role in potential protec-
tive effects. It was shown, for example, that the protective effect
of B*27 is dependent on the genotype, with genotype 1-infected
patients having T-cell responses against the protective B*27 epi-
tope, and genotype 3-infected patients showing no evidence of
T-cell responses to any epitope from the same region in the HCV
proteome, which differed in its sequence by three amino acids
(13). Our analysis focused on genotype 1 sequences (i.e., we use
genotype 1a and 1b reference strains in our in silico analysis and
analyze only experimentally verified CTL epitopes from genotype
1 sequences), as HLA associations taken into account here were
defined largely in the context ofHCVgenotype 1 infections.When
more sequence and epitope data become available from the other
genotypes, it will be possible to repeat our analysis on a genotype
basis.
So far, there is no direct evidence that targeting more con-
served HCV proteins by CD8+ T cells helps controlling HCV
replication. However, it has been widely argued that CD8+ T-
cell responses specific for conserved regions of HIV-1 (especially
Gag p24) should slow down disease progression (17, 38, 41). As
in the case of HIV-1, the most conserved HCV proteins are also
the most functionally and structurally constrained ones, which
makes it more difficult for the pathogen to escape from host
immune control in these proteins than in other regions. In line
with this reasoning, it has been shown that a point mutation
within a B*27 restricted dominant T-cell epitope in NS5B (pos.
421-429, ARMILMTHF) entails a large fitness cost (15). A study
of viral evolution in non-structural proteins during the acute
phase of HCV infection showed that mutations in this NS5B
epitope are also found and maintained in subjects that are not
B*27 positive (42). This lack of reversion over time suggests that
additional (compensatory) mutations must have occurred, which
do not allow simple reversion. Moreover, a rare mutation in the
anchor residue of a subdominant B*27 restricted NS5B epitope
(pos. 516-524, GRAAICGKY) was shown to nearly abrogate viral
replication, which could be restored by two upstream mutations
(38). Interestingly, also for B*57, it has been shown that mutations
in an NS5B epitope (pos. 209-217, KSKKTPMGF) substantially
impaired viral replication, which was restored by compensatory
mutations further upstream (14). Another recent study found that
B*57-positive HCV-infected chronic carriers harbor HCV strains
with a high frequency of mutations in key residues of this NS5B
epitope as well as in an E2 epitope [pos. 158-166, NTRPPLGNW;
Ref. (12)]. These epitope variants were also shown to be recog-
nized to a lesser extent in chronic carriers, which indicates that
presentation of these epitopes is important in viral clearance.
Unfortunately, to our knowledge, none of the other knownB*57 or
B*27 epitopes were studied in such detail. Still, these data indicate
that NS5B is a highly constrained region of the HCV genome
and shed some light on why immune responses targeting this
conserved protein of HCV might result in a favorable infection
outcome.
We wish to stress that the research presented in this article
is exploratory and that more clinical data are required to test
the mechanistic hypothesis suggested by our results. Specifically,
the sixteen predicted epitopes shown in Table 3 should be good
CTL targets, as they have low entropy and high predicted binding
affinity. This prediction is testable by measuring CTL responses
against these epitopes in vivo and correlating the strength of
immune escapes against these epitopes to the ability to clear the
HCV infection.
Going beyond hepatitis C infections, we believe that the
methodology we developed here for measuring HLA protein tar-
geting and epitope distributions may be useful for studying class
I responses to other infections as well. To explore the epitope
distributions identified in this study for both experimentally veri-
fied and in silico predicted epitopes, we have generated the “HCV
epitope browser” – an extended, interactive version of Figure 4.
This tool is available at theory.bio.uu.nl/ucqi/hcv.
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